Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Episode 11: Longer-term Results of Aflibercept in Cases of Neovascular AMD Incompletely Responsive to Other Anti-VEGF Agents

Retina Today Journal Club moderator Jonathan L. Prenner, MD, and study author Franco M. Recchia, MD, discuss data on patients who were switched to aflibercept (Eylea, Regeneron Pharmaceuticals) after they were unable to achieve a dry retina with other anti-VEGF agents—the so-called “switchers.”

The study evaluated 42 patients 1 year after they switched anti-VEGF therapy. Dr. Recchia discloses the study design and its findings and talks about how these data has affected the way he treats these patients since the study.


42 / 52 Series: Retina Today Journal Club


More Videos in this Series